Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real-World Observation Using a Nationwide, Population-Based Cohort.
Jae-Hyun LimSoongu KwakYou-Jung ChoiTae-Min RheeChan Soon ParkBongseong KimKyung-Do HanHeesun LeeJun Bean ParkYong-Jin KimHyun-Jung LeeHyung Kwan KimPublished in: Journal of the American Heart Association (2024)
This real-world, population-based study demonstrates that patients with type 2 diabetes using dapagliflozin may have a lower risk of developing nonvalvular atrial fibrillation than those using empagliflozin.